Silence Therapeutics CEO Ali Mortazavi on leave of absence
Mr. Mortazavi joined Silence in August 2012 as director of corporate strategy. He has more than 17 years of experience in financial services. He started his career as a Technology Analyst at Duncan Lawrie then Credit Lyonnais Securities.
Mr. Mortazavi co-founded Evolution Securities and ran the principal trading and market making arm. He has extensive experience in small companies and has had significant stakes in UK listed technology and biotech ventures.
The Company's Non-Executive Chairman, Alastair Riddell, will take on the role of Executive Chairman on an interim basis, until Ali Mortazavi's return.
Mr. Riddell joined the Board of Silence in November 2013 and was appointed Non-Executive Chairman in January 2015. He has 32 years of experience in the biopharmaceutical sector, including 15 years as CEO and Chairman of several UK biotechs. ■